Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $24.6 million.

  • Adma Biologics' Operating Expenses rose 2294.09% to $24.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.3 million, marking a year-over-year increase of 3846.82%. This contributed to the annual value of $80.6 million for FY2024, which is 1969.99% up from last year.
  • Per Adma Biologics' latest filing, its Operating Expenses stood at $24.6 million for Q3 2025, which was up 2294.09% from $24.4 million recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' Operating Expenses peaked at $26.2 million during Q1 2025, and registered a low of $13.4 million during Q1 2021.
  • Moreover, its 5-year median value for Operating Expenses was $17.3 million (2023), whereas its average is $18.8 million.
  • Examining YoY changes over the last 5 years, Adma Biologics' Operating Expenses showed a top increase of 15546.28% in 2021 and a maximum decrease of 5015.58% in 2021.
  • Over the past 5 years, Adma Biologics' Operating Expenses (Quarter) stood at $16.7 million in 2021, then increased by 21.15% to $20.2 million in 2022, then decreased by 16.72% to $16.9 million in 2023, then soared by 48.4% to $25.0 million in 2024, then decreased by 1.58% to $24.6 million in 2025.
  • Its Operating Expenses stands at $24.6 million for Q3 2025, versus $24.4 million for Q2 2025 and $26.2 million for Q1 2025.